Aims
Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. Data on its incidence, management and outcome are sparse.
Methods and results
This international multicenter registry investigates the characteristics of oesophageal fistulae after treatment of atrial fibrillation by catheter ablation. A total of 553,729 catheter ablation procedures (radiofrequency: 62.9%, cryoballoon: 36.2%, other modalities: 0.9%) were performed at 214 centers in 35 countries. In 78 centers 138 patients (0.025%, radiofrequency: 0.038%, cryoballoon: 0.0015% (p<0.0001)) were diagnosed with an oesophageal fistula. Periprocedural data were available for 118 patients (85.5%). Following catheter ablation, the median time to symptoms and the median time to diagnosis were 18 (7.75, 25; range: 0-60) days and 21 (15, 29.5; range: 2-63) days, respectively. The median time from symptom onset to oesophageal fistula diagnosis was 3 (1, 9; range: 0-42) days. The most common initial symptom was fever (59.3%). The diagnosis was established by chest computed tomography in 80.2% of patients. Oesophageal surgery was performed in 47.4% and direct endoscopic treatment in 19.8%, and conservative treatment in 32.8% of patients. The overall mortality was 65.8%. Mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower as compared to conservative management (89.5%) (odds ratio 7.463 (2.414, 23.072) p<0.001).
Conclusions
Oesophageal fistula after catheter ablation of atrial fibrillation is rare and occurs mostly with the use of radiofrequency energy rather than cryoenergy. Mortality without surgical or endoscopic intervention is exceedingly high.
The present study demonstrates safety and efficacy of a systematic transradial access for left ventricular EMB using a highly hydrophilic sheathless guiding catheter. This is of clinical importance since this new technique may overcome critical limitations of the common approach.
Introduction: Procedural atrial fibrillation (AF) termination is considered as a predictor of long-term success after catheter ablation for persistent AF (persAF).However, some patients remain free of arrhythmia recurrences despite failure to achieve AF termination. The objective of this study was to assess long-term outcome and prognostic factors in patients undergoing complex ablation without procedural AF termination.Methods and Results: This study comprised 419 patients (63.8 ± 10.2 years, 63.4% male) undergoing complex ablation for persAF. Patients without procedural AF termination (n = 137, 64.2 ± 9.7 years, 63.5% male) were categorized into patients who remained in sinus rhythm (SR) in long-term outcome (SR-group) and patients with recurrence of AF or atrial tachycardia (AT) (AR-group). During a follow-up (FU) of 19.6 ± 14.6 months, the SR-group consisted of 65 (47.5%) and the AR-group of 69 (50.4%) patients. Three patients (2.2%) were lost to FU. Left atrial appendage (LAA) flow velocity and left atrium volume index (LAVI) could be identified as predictors for long-term success. LAA flow velocity and baseline AF cycle length (AFCL) were significantly associated with the type of arrhythmia recurrence (AF vs AT), ie, higher values of both are predictive for AT rather than AF recurrences. Patients with a LAVI < 34.4 mL/m² and significant AFCL increase during the ablation procedure had rather AT than AF recurrences.
Conclusion:Patients with an arrhythmia-free outcome despite failure of procedural AF termination during complex ablation for persAF are characterized by specific morphological and functional properties that are easy to obtain. K E Y W O R D S ablation, atrial fibrillation, cycle length, left atrial appendage flow velocity, left atrial dilatation, predictors, termination
Funding Acknowledgements
Type of funding sources: None.
Background
Ultra-high-power short-duration (UHPSD) ablation with the novel QDOT™ catheter allows to maintain a target temperature by automatically adjusting flow and power during a 4-second application of 90 Watt. However, the optimal contact-force for a sufficient lesion generation is yet to be determined.
Methods
This study comprised 41 patients with symptomatic atrial fibrillation undergoing pulmonary vein isolation (PVI) with the QDot catheter using the UHPSD mode with 90 W for 4 seconds. All UHPSD applications for circumferential PVI were analyzed. Suboptimal UHPSD applications were defined as either an impedance drop of ≤5% or a cumulative temperature-limited energy ≤330 W.
Results
A total of 1904 UHPSD applications (46.4 applications per patient) were performed with an average contact force (aCF) of 12.3±6.4 g with a mean maximum temperature (maxTemp) of 48.4±3.8 °C and a mean impedance drop (ImpDrop) of 10±3.2%. An ImpDrop ≤5% occurred in 67 (3.5%) UHPSD applications which was associated with lower aCF (10.6±7 vs. 12.4±6.4 g; p=0.024) and a lower maxTemp (45.8±3.8 vs. 48.5±3.8 °C; p<0.001) as compared to UHPSD applications with an ImpDrop >5%. A cumulative energy ≤330 W was observed in 39 (2%) UHPSD applications. Interestingly, low cumulative energy UHPSD applications (≤330 W) were characterized by a higher aCF (21±9.6 vs. 12.1±6.2 g; p<0.001). Furthermore, low cumulative energy was observed significantly more often in UHPSD applications with aCF <5.6 g or >21.1 g (10.2% vs 3.6%; p=0.004).
Conclusion
A low but also a high contact-force (<6 and >21g) are associated with suboptimal UHPSD applications. Thus, UHPSD applications require a ’15-gram window’ of contact-force to achieve an optimal cumulative energy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.